OSR Health, Inc. (OSRH) - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2026. OSR Health, Inc. (formerly OSR Holdings, Inc.) is a global healthcare company operating through five wholly-owned subsidiaries. Its portfolio includes oral immunotherapies for cancer, design-augmented biologics, neurovascular intervention medical device distribution in Korea, and non-invasive biosensing technologies for blood glucose monitoring. The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Net Sales | $315,669 | $799,727 |
| Gross Profit | $86,605 | $246,886 |
| Gross Margin | 27.4% | 30.9% |
| Operating Loss | $(3,032,915) | $(6,700,098) |
| Net Loss (Consolidated) | $(1,004,038) | $(4,471,212) |
| Net Loss (Attributable to OSR Health) | $(848,905) | $(3,780,366) |
| Cash and Cash Equivalents | $1,499,603 | $1,499,603 |
| Total Debt (Short-term + Long-term) | $5,428,648 | $5,428,648 |
| Accumulated Deficit | $(40,950,247) | $(40,950,247) |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 72% ($819,848) for the three months ended June 30, 2026, compared to the same period in 2025. This was driven by a shift in the subsidiary RMC's business model from a purchase-and-resale model to a consignment-based arrangement, which recognizes only commission revenue rather than full sales value.
- Margin Expansion: Despite lower revenue, gross profit increased 165% to $86,605, and gross margin improved from 3% to 27% due to the aforementioned contractual change with a major supplier.
- Operating Loss Reduction: Operating loss decreased 42% to $(3.03) million for the quarter, primarily due to a 41% reduction in Selling, General, and Administrative (SG&A) expenses compared to the prior year, which included significant one-time business combination costs in 2025.
- Other Income: The company recorded a significant "Other income" of $1.80 million for the quarter, driven by a realized gain of $1.80 million on financial liabilities measured at fair value, resulting from the resolution of a previously recognized unrealized loss.
- Acquisition: The company acquired Woori-IO Co., Ltd. (a medical device and digital health platform company) in January 2026, recognizing $6.4 million in goodwill.
Guidance, Outlook, and Risks
- Liquidity and Capital Resources: The company has an accumulated deficit of approximately $41 million and relies on equity financing. It maintains an Equity Line of Credit (ELOC) with White Lion Capital, under which it has raised $3.38 million to date. Management intends to utilize the ELOC until December 31, 2026, while exploring less dilutive financing options like At-the-Market (ATM) offerings.
- R&D Outlook: Current R&D expenses are low due to funding constraints. Management estimates future R&D expenses could range from $2.5 million to $3.0 million per quarter, potentially rising to $5.0 million to $6.0 million per quarter if financing efforts succeed.
- Shareholder Loyalty Program: In June 2026, the company announced a Contingent Value Right (CVR) program. Shareholders who enroll and hold shares through specific measurement dates over 12 months may receive up to five additional shares for each share held if price thresholds ($2.00 to $5.00) are met.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2026, due to unremediated material weaknesses regarding the completeness of liabilities and sufficiency of accounting personnel.
- Legal Proceedings: The company is involved in pending litigation, including a civil action by Benjamin Securities, Inc. seeking $425,000 in fees, and a breach of contract complaint filed by Chardan Capital Markets, LLC.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.5 million cash balance against the projected quarterly burn rate and the availability of the remaining ELOC capacity.
- Revenue Sustainability: Confirm the long-term viability of the consignment model with RMC's major supplier and the impact on future revenue recognition.
- Internal Control Remediation: Review the specific timeline and progress for remedying the material weaknesses in internal controls over financial reporting.
- Legal Exposure: Assess the potential financial impact of the pending lawsuits with Benjamin Securities and Chardan Capital Markets.
- Dilution Risk: Evaluate the potential dilution from the ELOC, the CVR program, and the convertible notes issued to White Lion Capital.